Cargando…
Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus
Alemtuzumab is a humanized monoclonal antibody indicated for the treatment of adult patients with relapsing–remitting multiple sclerosis with active disease. Multiple sclerosis (MS) patients treated with alemtuzumab are at increased risk for autoimmune adverse events (thyroid disorders, immune throm...
Autores principales: | Sprangers, Ben, Decoo, D., Dive, D., Lysandropoulos, A., Vanopdenbosch, L., Bovy, C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971040/ https://www.ncbi.nlm.nih.gov/pubmed/29189966 http://dx.doi.org/10.1007/s13760-017-0864-x |
Ejemplares similares
-
Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus
por: Lambert, Catherine, et al.
Publicado: (2018) -
Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management
por: Decallonne, Brigitte, et al.
Publicado: (2018) -
A Belgian consensus on the definition of a treat‐to‐target outcome set in psoriasis management
por: Grine, L., et al.
Publicado: (2020) -
Consensus on targeted drug therapy for spondyloarthritis
por: Tian, Xinping, et al.
Publicado: (2023) -
European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update
por: Sweet, David G., et al.
Publicado: (2023)